← Back to Search

Enhanced Screening for Lung Cancer (TEALS Trial)

N/A
Recruiting
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults aged 50-80
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

TEALS Trial Summary

This trial will study how to best implement a low-dose computed tomography screening program for lung cancer in American Indian and Alaska Native communities in order to reduce mortality rates.

Who is the study for?
The TEALS trial is for American Indian and Alaska Native adults aged 50-80 who have a history of heavy smoking (30 pack-years), including current smokers or those who quit within the last 15 years. It's not for individuals whose doctors decide they won't benefit from screening, or those unwilling to undergo follow-up tests or treatments if needed.Check my eligibility
What is being tested?
TEALS is testing enhanced lung cancer screening services in tribal healthcare systems. The study includes focus groups, development of care coordination interventions, and measures the impact through a cluster-randomized clinical trial to improve early detection and reduce mortality in AI/AN communities.See study design
What are the potential side effects?
Since this trial focuses on lung cancer screening rather than medication or invasive procedures, there are no direct side effects like you'd expect with drugs. However, participants may experience anxiety related to screening results and potential follow-up procedures.

TEALS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 80 years old.

TEALS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
1. Health system-level care process outcomes
1. Uptake of low-dose computed tomography lung cancer screening services
2. Health system-level care process outcomes
+6 more
Secondary outcome measures
ACIC
CAHPS
CPCQ
+4 more

TEALS Trial Design

7Treatment groups
Experimental Treatment
Group I: Intervention 1-5Experimental Treatment1 Intervention
In addition to control group improvements, patients and clinicians in the intervention group will also receive information technology support.
Group II: Intervention 1-4Experimental Treatment1 Intervention
In addition to control group improvements, patients and clinicians in the intervention group will also receive the opportunity to participate in a learning collaborative.
Group III: Intervention 1-3Experimental Treatment1 Intervention
In addition to control group improvements, patients and clinicians in the intervention group will also receive practice facilitation.
Group IV: Intervention 1-2Experimental Treatment1 Intervention
In addition to control group improvements, patients and clinicians in the intervention group will also receive quality of care benchmarking and feedback academic detailing.
Group V: Intervention 1-1Experimental Treatment1 Intervention
In addition to control group improvements, patients and clinicians in the intervention group will also receive an LCS Care Coordinator.
Group VI: Control 1-2Experimental Treatment1 Intervention
Patients and Clinicians in control practices will have access to existing LCS services, smoking cessation, and lung cancer treatment services, but no additional system improvements will be introduced.
Group VII: Control 1-1Experimental Treatment1 Intervention
Patients and clinicians in control practices will receive usual Electronic Health Record (EHR) reminders for lung cancer screening (LCS).

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor
455 Previous Clinical Trials
97,821 Total Patients Enrolled
Choctaw Nation of OklahomaUNKNOWN
1 Previous Clinical Trials
630 Total Patients Enrolled

Media Library

Enhanced lung cancer screening services Clinical Trial Eligibility Overview. Trial Name: NCT04948060 — N/A
Lung Cancer Research Study Groups: Intervention 1-5, Intervention 1-4, Control 1-1, Intervention 1-1, Control 1-2, Intervention 1-2, Intervention 1-3
Lung Cancer Clinical Trial 2023: Enhanced lung cancer screening services Highlights & Side Effects. Trial Name: NCT04948060 — N/A
Enhanced lung cancer screening services 2023 Treatment Timeline for Medical Study. Trial Name: NCT04948060 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research include elderly individuals more than 85 years of age?

"Those aged between 50 and 80 years are eligible to be accepted into this clinical trial."

Answered by AI

Is this research project presently recruiting new participants?

"Per the information on clinicaltrials.gov, this medical trial requires additional participants and was first made public on October 1st 2021. The posting has been updated as recently as November 7th 2022."

Answered by AI

What is the maximum number of participants allowed in this experiment?

"Affirmative. The information published to clinicaltrials.gov confirms that this is a currently active trial, which was initially posted on October 1st 2021 and recently revised on November 7th 2022. A total of 480 patients are needed from one single medical site for the study to proceed."

Answered by AI

Which individuals are eligible to join this trial?

"This research is seeking 480 participants aged between 50 and 80 with a history of smoking that amounts to at least 30 pack-years. They must also meet both age criteria (50 - 80) and be either current or former smokers within the past 15 years."

Answered by AI

What objectives is this clinical trial striving to accomplish?

"This year-long clinical trial sets out to gauge the uptake of lung cancer screening services through low-dose computed tomography. As secondary objectives, semi-structured interviews with patients, clinicians and health system leaders will be conducted for qualitative assessment on barriers and facilitators in patient participation of TEALS program as well assessing Chronic Illness Care (ACIC) scales at end Year 3 and 4."

Answered by AI
~176 spots leftby Jun 2025